ReviewAdvanced drug delivery reviews2012
RNA therapeutics targeting osteoclast-mediated excessive bone resorption.
Review in Advanced drug delivery reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 46 citations in OpenAlex.
- Scaffold-Mediated Microenvironmental Modulation Targeting Osteoclasts for ONFH Niche Reprogramming.Research (Washington, D.C.) · 2025Review
- Mechanism of Efferocytosis in Determining Ischaemic Stroke Resolution-Diving into Microglia/Macrophage Functions and Therapeutic Modality.Molecular neurobiology · 2024Review
- MicroRNA binding site variants-new potential markers of primary osteoporosis in men and women.Frontiers in genetics · 2024Article
- Advantages of Material Biofunctionalization Using Nucleic Acid Aptamers in Tissue Engineering and Regenerative Medicine.Molecular biotechnology · 2023Review
- Downregulation of the RNA-binding protein PUM2 facilitates MSC-driven bone regeneration and prevents OVX-induced bone loss.Journal of biomedical science · 2023Article
- Pyroptosis in bone loss.Apoptosis : an international journal on programmed cell death · 2023Review
- Nitric Oxide-Releasing Bioinspired Scaffold for Exquisite Regeneration of Osteoporotic Bone via Regulation of Homeostasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Regulation of osteoclast-mediated bone resorption by microRNA.Cellular and molecular life sciences : CMLS · 2022Review
- High-salt diet downregulates TREM2 expression and blunts efferocytosis of macrophages after acute ischemic stroke.Journal of neuroinflammation · 2021Article
- Cinnamtannin B-1 Prevents Ovariectomy-Induced OsteoporosisFrontiers in pharmacology · 2020Article
- Bisphosphonate conjugation for bone specific drug targeting.Bone reports · 2018Review
- Nanoparticles Based on Poly (β-Amino Ester) and HPV16-Targeting CRISPR/shRNA as Potential Drugs for HPV16-Related Cervical Malignancy.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Small non-coding RNAs-based bone regulation and targeting therapeutic strategies.Molecular and cellular endocrinology · 2017Review
- A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy.International journal of nanomedicine · 2017Article
- Biomaterial strategies for engineering implants for enhanced osseointegration and bone repair.Advanced drug delivery reviews · 2015Review
- Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2.Molecular therapy. Nucleic acids · 2015Article
- Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy.Nature medicine · 2015Article
- Developing siRNA therapies to address osteoporosis.Therapeutic delivery · 2013Review
- Selective local delivery of RANK siRNA to bone phagocytes using bone augmentation biomaterials.Biomaterials · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
RNA interference (RNAi) is a sequence-specific post-transcriptional gene silencing technique developed with dramatically increasing utility for both scientific and therapeutic purposes. Short interfering RNA (siRNA) is currently exploited to regulate protein expression relevant to many therapeutic applications, and commonly used as a tool for elucidating disease-associated genes. Osteoporosis and their associated osteoporotic fragility fractures in both men and women are rapidly becoming a global healthcare crisis as average life expectancy increases worldwide. New therapeutics are needed for this increasing patient population. This review describes the diversity of molecular targets suitable for RNAi-based gene knock down in osteoclasts to control osteoclast-mediated excessive bone resorption. We identify strategies for developing targeted siRNA delivery and efficient gene silencing, and describe opportunities and challenges of introducing siRNA as a therapeutic approach to hard and connective tissue disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.